人源化肝癌抗体研制应用前景的分析

非手术治疗是肝癌治疗的重要方面 ,放疗与化疗由于治疗药物对肿瘤组织特异性差 ,对肿瘤外组织有很大的毒副作用 ,经放疗或化疗后的患者生活质量受到很大影响 ,甚至可能会危及生命。肝癌的生物治疗尤其是特异性抗体的针对性治疗成为人们日益关注的焦点。但是从 1975年开始研制了近 2 0年的鼠源性的抗体并不能有效的激发人类效应器的功能 ,却会引发人抗鼠抗体的形成 ,从而引起严重的副反应。DNA重组技术的应用为解决免疫导向存在的问题提供有效的技术手段。鼠单抗人源化与噬菌体人抗体库技术为肝癌治疗提供了新的方法和策略。而国内用于肿瘤治疗的单抗产品均为鼠源或人源化鼠抗体 ,人源抗体的研究还处于初期阶段 ,无相关产品问世 ,而美国FDA从 2 0 0 1年起已不再批准非人源抗体用于人体的临床试验。从发展趋势看 ,人源抗体的研制将会迅速占领市场 ,采用噬菌体抗体库技术研制人源肝癌治疗性抗体将会有良好的应用前景

Application prospects of human-originated hepatocellular carcinoma antibodies

Non-surgical therapy is important to liver cancer treatment. Actinotheraphy and chemotherapy, because of their less specific for cancer tissue and serious side effect, badly affect the patients' life qualities, sometimes even endanger the patients lives. Hepatocellular carcinoma specific antibodies have been the focus of liver cancer biotherapy. After 20 years of study since 1975, it has been demonstrated that antibodies derived from mouse could not efficiently stimulate the functions of human reactor, but could induce human anti-mouse antibody responses which could bring about serious side effects. The application of DNA recombination technique provides a good method for resolving the immune selection problem. The techniques of humanoriginated antibodies and phage displaying will lead to development of innovative strategies to manage liver cancer. In our country, the antibody products aimed at cancer all originated from mouse while the study of human antibodies is still at its primary stage. Non-human antibodies has been forbidden in clinical trails by FDA in America since 2001. It can be speculated that human antibody products will domminate the future market rapidly.